Completed Trials of the GCLLSG
- CLL1
- Prognostic factors and risk-adapted therapy in patients with early stage chronic lymphocytic leukemia
- » more
- CLL2
- Multizentrische Phase II-Studie zur Evaluation von höher dosiertem Chlorambucil und von
Fludarabin-Cyclophophamid bei forgeschrittener chronischer lymphatischer Leukämie
- CLL2B
- Treatment of patients with chronic lymphocytic leukemia with anti-CD20 antibody rituximab (IDEC-C2B8)
- CLL2C
- Treatment of patients with chronic lymphocytic leukemia using fludarabine and the anti-CD20 antibody
Rituximab (IDEC-C2B8)
- » more
- CLL2D
- Phase I/II-Studie zur Evaluation von Treosulfan bei fortgeschrittener chronischer lymphatischer Leukämie
- CLL2E
- Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: a
phase I/II study of the German CLL Study Group
- » more
- CLL2F
- Erhaltungstherapie mit Rituximab bei therapierefraktärer oder rezidivierter B-CLL
Multizentrische Phase-II-Studie
- Diese Studie wurde nicht gestartet.
- CLL2G
- CHOP plus Rituximab (CHOP-R) in fludarabine refractory chronic lymphocytic leukemia (CLL) or
CLL with autoimmune haemolytic anemia (AIHA) or Richter’s transformation (RT)
- » more
- CLL2H
- Subcutaneous Campath-1H (Alemtuzumab; MabCampath®) in fludarabine-refractory CLL
- » more
- CLL2i
- Consolidation therapy with Alemtuzumab (MabCampath ®) in patients with chronic lymphocytic
leukemia who are in complete or partial 2nd remission after cytoreduction with
fludarabine or fludarabine plus cyclophosphamide or fludarabine plus cyclophosphamide plus
rituximab or bendamustine or bendamustine plus rituximab - a phase I/II study
- » more
- CLL2K
- Treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) with Bendamustin / Mitoxantrone (BM)
- » more
- CLL2L
- Multicenter phase II trial of fludarabine and cyclophosphamide in combination with
alemtuzumab for patients with relapsed or high risk chronic lymphocytic leukemia (FC-Cam)
- » more
- CLL2M
- Multicentre phase II trial of Bendamustine in combination with rituximab for patients
with previously untreated or relapsed chronic lymphocytic leukemia
- » more
- CLL2O
- A prospective, multi-center phase II study of subcutaneous alemtuzumab
combined with oral dexamethasone, followed by alemtuzumab maintenance
or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia
which is associated with 17p deletion or is refractory to fludarabine
- » more
- CLL2P
- A phase I/II safety and efficacy trial of a combination of
bendamustine, rituximab and lenalidomide (BRL) with
relapsed or refractory chronic lymphocytic leukemia (CLL)
and a phase II efficacy trial for patients with previously
untreated CLL
- » more
- CLL2s
- A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and
Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic
Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or
Purine Analogue-based Therapy
- » more
- CLL2-BIG
- A prospective, open-label, multicenter phase-II trial to evaluate the
efficacy and safety of a sequential regimen of bendamustine followed
by GA101 and ibrutinib (BIG) followed by GA101 and ibrutinib
maintenance in CLL patients
- » more
- CLL2-BIO
- A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety
of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib
and ofatumumab maintenance in CLL patients
- » more
- CLL3
- Pivotal Study for high dose therapy and autologous stem cell transplantation in early stages of CLL
- » more
- CLL3C
- Campath-1H (Alemtuzumab) in Kombination mit Hochdosistherapie und autologer
Stammzelltransplantation bei Patienten mit chronischer lymphatischer Leukämie
- CLL3R
- The value of autografting in patients with high-risk chronic lymphocytic leukemia. A
randomized phase III intergroup trial.
This trial was prematurely terminated due to poor accrual.
- » more
- CLL3X
- Pilot study on allogeneic stem cell transplantation following conditioning with fludarabine
and an alkylating agent in patients with high-risk chronic lymphocytic leukemia
- » more
- CLL4
- Fludarabine versus fludarabine plus cyclophosphamide in first line therapy of younger
patients (up to 65 years) with advanced chronic lymphocytic leukemia (CLL)
- » more
- CLL4B
- Consolidation therapy with CAMPATH-1H (alemtuzumab ) in patients ≤ 65 years with
chronic lymphocytic leukemia who are in complete or partial remission after initial
cytoreduction with fludarabine or fludarabine plus cyclophosphamide
- » more
- CLL5
- Fludarabine versus chlorambucil in first line therapy of elderly patients
(more than 65 years) with advanced chronic lymphocytic leukemia (CLL)
- » more
- CLL6
- Treatment of advanced chronic lymphocytic leukemia (CLL) fludarabine,
mitoxantrone and cyclophosphamide combination with or without G-CSF
- CLL7
- Randomized phase III trial comparing early treatment with
fludarabine/cyclophosphamide + rituximab versus deferred
treatment in untreated Binet stage A patients with high risk of progression
CLL7 protocol of the GCLLSG and FCGCLL
- » more
- CLL8
- Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide
and Rituximab (FCR) versus chemotherapy with Fludarabine and Cyclophosphamide (FC)
alone in patients with previously untreated chronic lymphocytic leukaemia
CLL-8 / ML17102 Protocol of the German CLL Study Group (GCLLSG)
- » more
- CLL9
- Darbepoetin alfa in patients with chronic lymphocytic leukamia and comorbidity
- » more
- CLL10
- Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and
Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously
untreated chronic lymphocytic leukaemia
- » more
- CLL11
- An open-label, multi-center, three arm randomized, phase III study to compare
the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb) or
chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities
- » more
- LGL1
- First line therapy with methotrexate (MTX) and second line therapy with fludarabine of patients with T-cell large granular lymphocyte leukemia (T-LGL)
- » more
- PLL1
- Phase-II-trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab in patients with B-PLL
- » more
- T-PLL1
- Fludarabine, Mitoxantrone and Cyclophosphamide (FMC) in T-CLL and T-PLL followed by Alemtuzumab as consolidation
- » more
- T-PLL2
- Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia
- » more
